Apolizumab (HLA-DRB) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-067-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-nd
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
Hu1D10, HLA-DRB, HLA-DRB
Background:
Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.Apolizumab is a humanized monoclonal antibody directed against 1D10,a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells.Apolizumab induces complement-mediated cytotoxicity,antibody-dependent cell-mediated cytotoxicity,and apoptosis of 1D10 antigen-positive B cells in vitro.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Humanized / HLA-DRB [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
Swissprot #:
P01730
User NOte:
Optimal dilutions for each application to be determined by the researcher.